RGTP.Q Stock Overview
A clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
RegenETP, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$0.22 |
| 52 Week Low | US$0.0026 |
| Beta | 0 |
| 11 Month Change | 26.95% |
| 3 Month Change | 788.67% |
| 1 Year Change | 441.87% |
| 33 Year Change | -98.64% |
| 5 Year Change | -99.81% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
PolarityTE down 10% on lower-than-expected Q2 revenue
Aug 12Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?
Mar 08
Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation
Nov 16PolarityTE Is Not A DeFi Coin
Jul 19Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?
Jun 04PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint
May 10What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition
Feb 19
PolarityTE to raise up to $10M with at-the-market offering
Jan 12PolarityTE under pressure on pricing $8M registered direct offering
Dec 22PolarityTE perks up after securing first U.S. patent
Nov 30PolarityTE EPS beats by $0.02, beats on revenue
Nov 09Shareholder Returns
| RGTP.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 20.0% | 2.5% | 1.0% |
| 1Y | 441.9% | 15.6% | 31.4% |
Return vs Industry: RGTP.Q exceeded the US Biotechs industry which returned 15.6% over the past year.
Return vs Market: RGTP.Q exceeded the US Market which returned 30.7% over the past year.
Price Volatility
| RGTP.Q volatility | |
|---|---|
| RGTP.Q Average Weekly Movement | 35.1% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGTP.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RGTP.Q's weekly volatility has decreased from 290% to 35% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 43 | Richard Hague | www.polarityte.com |
RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.
RegenETP, Inc. Fundamentals Summary
| RGTP.Q fundamental statistics | |
|---|---|
| Market cap | US$799.18k |
| Earnings (TTM) | -US$8.30m |
| Revenue (TTM) | US$73.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs RGTP.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGTP.Q income statement (TTM) | |
|---|---|
| Revenue | US$73.00k |
| Cost of Revenue | US$125.00k |
| Gross Profit | -US$52.00k |
| Other Expenses | US$8.25m |
| Earnings | -US$8.30m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RGTP.Q perform over the long term?
See historical performance and comparison